Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study-Reference-Cited by-同舟云学术

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Published:2021-07 Issue:7 Volume:22 Page:1034-1046
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pujade-Lauraine Eric,Fujiwara Keiichi,Ledermann Jonathan A,Oza Amit M,Kristeleit Rebecca,Ray-Coquard Isabelle-Laure,Richardson Gary E,Sessa Cristiana,Yonemori Kan,Banerjee Susana,Leary Alexandra,Tinker Anna V,Jung Kyung Hae,Madry Radoslaw,Park Sang-Yoon,Anderson Charles K,Zohren Fabian,Stewart Ross A,Wei Caimiao,Dychter Samuel S,Monk Bradley J

Funder

Pfizer Inc Boulder

Merck KGaA

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

2. Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity;Hao;Clin Cancer Res,2018

3. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer;Zhang;Cell,2018

4. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer;Goode;JAMA Oncol,2017

5. Ovarian cancer creates a suppressive microenvironment to escape immune elimination;Yigit;Gynecol Oncol,2010

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study;British Journal of Cancer;2024-09-11

2. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

3. Clinical and molecular features of platinum resistance in ovarian cancer;Critical Reviews in Oncology/Hematology;2024-09

4. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer;Gynecologic Oncology;2024-09

5. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors;Cell;2024-09